0      0

JL1105ES - JL1105ES: Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy

‐ Oct 30, 2023 11:00am

Full author listing 

Srikala S. Sridhar, MD, MSc, FRCPC, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada. Thomas Powles, MD, Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen

Mary University of London, St Bartholomew’s Hospital, London, UK. Shilpa Gupta, MD, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA. Miguel A. Climent Duran, MD, Instituto Valenciano de Oncología, Valencia, Spain. Jeanny B. Aragon-Ching, MD, FACP, Inova Schar Cancer Institute, Fairfax, VA, USA. Cora N. Sternberg, MD, FACP, Weill Cornell Medicine, Hematology/Oncology, Englander Institute for Precision Medicine, Meyer Cancer Center, New York, NY, USA. Paul Cislo, PhD, Pfizer, New York, NY, USA. Nuno Costa, MD, Pfizer, Porto Salvo, Portugal. Alessandra di Pietro, MD, PhD, Pfizer srl, Milano, Italy. Joaquim Bellmunt, MD, PhD, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Petros Grivas, MD, PhD, University of Washington; Fred Hutchinson Cancer Center, Seattle, WA, USA.


You must be logged in and own this session in order to post comments.